tiprankstipranks
Advertisement
Advertisement

XGN Stock Latest News

Exagen participates in a conference call with Craig-Hallum
The FlyExagen participates in a conference call with Craig-Hallum
7d ago
XGN
Exagen price target raised to $9 from $8 at BTIG
PremiumThe Fly
Exagen price target raised to $9 from $8 at BTIG
1M ago
XGN
Exagen price target raised to $12 from $8 at B. Riley
PremiumThe Fly
Exagen price target raised to $12 from $8 at B. Riley
1M ago
XGN
Exagen price target raised to $10 from $8 at TD Cowen
PremiumThe Fly
Exagen price target raised to $10 from $8 at TD Cowen
1M ago
XGN
Exagen price target raised to $9 from $8 at Canaccord
PremiumThe Fly
Exagen price target raised to $9 from $8 at Canaccord
1M ago
XGN
Exagen Earns Buy Rating as Strong Q2 Performance, Lower Cash Risk, and Growth Pipeline Drive Price Target Increase to $10
PremiumRatingsExagen Earns Buy Rating as Strong Q2 Performance, Lower Cash Risk, and Growth Pipeline Drive Price Target Increase to $10
1M ago
XGN
Exagen Earnings Call Highlights Record Growth And Margin Gains
Premium
Company Announcements
Exagen Earnings Call Highlights Record Growth And Margin Gains
1M ago
XGN
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
Premium
The Fly
Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M
1M ago
XGN
Exagen reports Q2 EPS (13c), consensus (17c)
PremiumThe Fly
Exagen reports Q2 EPS (13c), consensus (17c)
1M ago
XGN
XGN Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
XGN Upcoming Earnings Report: What to Expect?
1M ago
XGN
Spero Therapeutics appoints Debra Jeske Zack as chief medical officer
PremiumThe Fly
Spero Therapeutics appoints Debra Jeske Zack as chief medical officer
1M ago
XGN
SPRO
Roth starts Exagen at Buy, notes biomarker testing outperformance
PremiumThe Fly
Roth starts Exagen at Buy, notes biomarker testing outperformance
2M ago
XGN
Exagen initiated with a Buy at Roth Capital
PremiumThe FlyExagen initiated with a Buy at Roth Capital
2M ago
XGN
Exagen Shareholders Approve Directors, Auditor and Pay Package
Premium
Company Announcements
Exagen Shareholders Approve Directors, Auditor and Pay Package
3M ago
8K
XGN
Exagen Earnings Call Highlights Growth Amid Headwinds
Premium
Company Announcements
Exagen Earnings Call Highlights Growth Amid Headwinds
4M ago
XGN
Exagen Earnings Call Highlights Growth Amid Key Risks
PremiumCompany Announcements
Exagen Earnings Call Highlights Growth Amid Key Risks
4M ago
XGN
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
PremiumRatings
Exagen Wins Buy Rating on Strong Q1 Beat, Improving Fundamentals and Clear Path to EBITDA Breakeven
4M ago
XGN
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
PremiumRatings
Exagen: Buy Rating Reiterated as Strong Execution and Growth Outlook Support Unchanged $8 Price Target
4M ago
XGN
Exagen price target lowered to $8 from $9 at BTIG
PremiumThe Fly
Exagen price target lowered to $8 from $9 at BTIG
4M ago
XGN
Exagen’s Risk Profile Remains Unchanged: Stable Yet Persistent Exposures Keep Investors on Alert
PremiumCompany AnnouncementsExagen’s Risk Profile Remains Unchanged: Stable Yet Persistent Exposures Keep Investors on Alert
4M ago
XGN
Exagen reports Q1 EPS (17c), consensus (25c)
Premium
The Fly
Exagen reports Q1 EPS (17c), consensus (25c)
4M ago
XGN
Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M
Premium
The Fly
Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M
4M ago
XGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >